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Results: The impact of strictly switching all proton pump inhibitors 
to esomeprazole at admission resulted in a spillover “extra-cost” of 
€ 330.3 (95% CI, 276.1 to 383.8) thousand, whereas strictly switch-
ing to generic cetirizine resulted in savings of € 7.7 (95% CI, –11.1; 
–4.1) thousand. Over the entire study period, we estimated that the 
RDF resulted in “extra-costs” of € 503.6 (95% CI, 444.5 to 563.1) 
thousand.
Conclusion: Hospitals may contribute to increased overall health 
care costs if follow-on drugs are listed in the RDF. Therefore, health 
care providers and policy makers should be aware of the impact of 
evergreening strategies.
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Introduction: There have been variable measures introduced in 
Scotland in recent years to take advantage of the availability of gener-
ics in high volume classes. Consequently, there is a need to assess their 
influence to provide guidance to authorities for the future.
Patients (or Materials) and Methods: A mixture of retrospective 
observational studies and interrupted time series analyses on subse-
quent drug utilization (DDDs [defined daily doses]) and expenditure 
of the various drugs in the different classes. Only administrative data-
bases used. Demand side measures recorded and categorized by 4Es 
(education, engineering, economics, and enforcement).
Results: (1) Multiple demand-side measures led to low-cost generic 
proton pump inhibitors (PPIs) driving the increase in utilization in 
recent years. PPI expenditure in 2010 was 56% below 2001 levels 
despite a 3-fold increase in utilization. The multiple measures saved 
the Scottish NHS GB£159 mn in 2010. Similarly for the statins, 
expenditure in 2010 was only 7% above 2001 levels despite a 6.2-
fold increase in utilization. Savings through the multiple measures 
were estimated at GB£290 mn in 2010. There was also increasing 
utilization of higher strength statins following quality targets and 
SIGN guidance. (2) Expenditure on renin-angiotensin inhibitor drugs 
in 2007 was similar to 2001 with multiple reforms to limit utilization 
of angiotensin receptor blockers (ARBs). (3) No specific measures 
to enhance the prescribing of losartan (first ARB to lose its patent) 
versus other ARBs. This resulted in no change in the utilization 
of losartan postgenerics. (4) pragmatic approach to generic clopi-
dogrel resulted in continuing high INN prescribing for clopidogrel 
and associated savings. (5) Measures to encourage the prescribing 
of generic SSRIs versus escitalopram reduced SSRI expenditure, fall-
ing by 59% between 2001 and 2007, despite increased utilization. 
SSRI expenditure increased in countries with limited demand-side 
measures. (6) No change in the utilization of risperidone postgenerics 
with no specific measures encouraging its use versus other atypical 
antipsychotics (AAPs).
Conclusion: Multiple demand-side measures appreciably enhanced 
prescribing efficiency in Scotland. This was helped by high INN pre-
scribing rates (98% to 99% in all classes studied) and low costs for 
generics. There was no spillover effect between classes, even if closely 
related, to enhance the prescribing of generics first line where no 
active reforms (eg, losartan or risperidone). However, the complex-
ity of treating schizophrenia and bipolar disorders may limit the 
potential to enhance the prescribing of generic AAPs first line where 
appropriate.
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Introduction: Generic losartan has been available across Europe, 
providing opportunities for authorities to save costs as all angioten-
sin receptor blockers (ARBs) are seen as similar in treating hyper-
tension and heart failure at appropriate doses. However, initiatives 
vary across Europe. Consequently, there is a need to assess changes 
in losartan utilization versus other ARBs alongside accompanying 
demand-side measures to provide future guidance.
Patients (or Materials) and Methods: Retrospective observational 
study using an interrupted time series design of patients dispensed 
at least 1 ARB in Austria, Belgium, Denmark, England (Bury PCT), 
Scotland, Spain (Catalonia), and Sweden up to 3 years before generic 
losartan was reimbursed and to up 3 years after. Defined daily doses 
and only administrative databases were used. Demand-side measures 
were recorded under the 4Es (education, engineering, economics, and 
enforcement). Prices for generic losartan were also recorded.
Results: There was appreciable variation in health authority activity. 
This ranged from delisting of all other ARBs from the reimbursement 
list in Denmark; easing of prescribing restrictions for losartan but not 
for other ARBs in Austria and Belgium; and formularies, incentive 
programs, and therapeutic switching in NHS Bury and Sweden, to 
no targeted activities in Spain or Scotland (due to other activities and 
other ARBs shortly losing their patents). Significant changes were 
seen in losartan utilization in Denmark (losartan 93% of total ARBs 
by study end), NHS Bury (losartan 65% of total ARBs by the end of 
the study). However, no change in losartan utilization postgenerics 
until active measures) and Sweden (losartan 40% of total ARBs). 
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Significant but lesser changes in losartan utilization were seen in 
Austria and Belgium. There was no change in losartan utilization 
patterns in Scotland or Spain. Losartan typically generic at low prices, 
leading to appreciable increases in prescribing efficiency in NHS Bury, 
Sweden, Austria, and Belgium. There were some savings in Scotland 
with generic losartan.
Conclusion: Multiple demand-side measures appreciably enhanced 
ARB prescribing efficiency. This mirrors previous findings that mul-
tiple measures are need to change prescribing habits. No significant 
increase in losartan utilization following generics where countries 
have not instigated specific measures suggests authorities cannot rely 
on a “spillover” effect between classes to change physician prescrib-
ing habits. This is the case even with multiple demand-side activities 
encouraging preferential prescribing of generics in related classes. 
This may be exacerbated on this occasion by a more complex mes-
sage; for example, away from ACEIs first line versus ARBs to ACEIs 
+ low cost ARBs first line.
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Introduction: The availability of generic venlafaxine is an opportu-
nity for health authorities to save resources given the prevalence of 
depression. However, depression can be complex to treat, with physi-
cians reluctant to change prescriptions if patients are responding to a 
particular antidepressant. Consequently, there is a need to assess: (1) 
changes in the utilization pattern of venlafaxine versus other newer 
antidepressants before and after the availability of generic venla-
faxine and before and after prescribing restrictions were introduced 
for duloxetine in Sweden limiting prescribing to refractory patients; 
(2) utilization of generic versus originator venlafaxine; and (3) price 
reductions for generic venlafaxine and subsequent expenditure on 
newer antidepressants over time, to guide future reforms.
Patients (or Materials) and Methods: Interrupted time series ana-
lyzing the changes in aggregated dispensed prescriptions (DDDs 
[defined daily doses]) of patients dispensed at least 1 of the newer 
antidepressant from January 2007 to August 2011. This included 
time before the availability of generic venlafaxine to 19 months after 
the availability of generic venlafaxine but before prescribing restric-
tions introduced for duloxetine and to 13 months after prescribing 
restrictions were introduced for duloxetine. Expenditure measured, 
which included price reductions for generic venlafaxine over time.
Results: There was no appreciable change in the utilization of venla-
faxine after generic availability but before prescribing restrictions for 
duloxetine with no appreciable demand-side activities by the regions 
(counties) to preferentially encourage its prescribing. However, the 
utilization of venlafaxine significantly increased after the introduction 
of prescribing restrictions for duloxetine, although no appreciable 
change in the utilization of duloxetine. Principally, generic venlafax-
ine was prescribed and dispensed versus the originator once available. 
There was an appreciable fall in expenditure for venlafaxine follow-
ing generics that lead to a fall in expenditure for newer antidepres-
sants in Sweden after generic venlafaxine became available.
Conclusion: No apparent concerns with generic venlafaxine among 
physicians versus the originator. Multiple demand-side measures 
are needed to change physician prescribing habits. Authorities can-
not rely on a “spillover” effect between classes to change physician 
prescribing habits. The limited influence of prescribing restrictions 
on the subsequent utilization of duloxetine reflects the complexity 
of the disease area versus treating acid-related stomach disorders, 
hypercholesterolemia, or hypertension. However, the influence of the 
prescribing restrictions for duloxetine resulting in increased utiliza-
tion of venlafaxine is encouraging.
Funding Source: The project was part funded by a grant from the 
Karolinska Institutet
Disclosure of Interest: None declared.
PP064—AGRANULOCYTOSIS DETECTION 
OUTCOME BY CLOZAPINE TREATMENT (ADOC 
STUDY) IN PSYCHIATRY: A COST-EFFECTIVENESS 
STUDY
F.R. Girardin1,2*; A. Poncet3; M. Blondon3; V. Rollason4;  
N. Vernaz3; P. Dayer3; and C. Combescure3
1Division of clinical pharmacology and Toxicology, University 
Hospital of Geneva (HUG); 2Medical and Quality Directorate, 
University Hospitals of Geneva; 3HUG, Geneva, Switzerland; 
and 4Division of clinical pharmacology and Toxicology, HUG, 
Geneva, Switzerland
Introduction: White blood cell (WBC) monitoring is mandatory in 
several countries among schizophrenic patients treated by clozap-
ine, because of the risk of drug-induced agranulocytosis. Our aim is 
to compare the cost-effectiveness of 4 WBC- monitoring strategies 
(United Kingdom, United States, Switzerland, and an weekly short-
run monitoring) to the absence of monitoring.
Patients (or Materials) and Methods: We built a semi-Markovian 
model to conduct a cost-utility analysis from a health care perspective 
with a 3-year time horizon, assuming a probability of agranulocytosis 
of 0.7% at 3 years. Clinical and resources used parameters were 
based on national clozapine patients’ registries, cohorts, and Swiss 
pharmacovigilance data; health-related quality of life and mortality 
estimates were derived from literature reviews. Model uncertainty 
was was assessed with 1-way and probabilistic sensitivity analyses.
Results: In our model, compared with the absence of monitoring, all 
4 monitoring strategies increased the quality-adjusted survival simi-
larly by < 1 day, with 5000 patients to monitor to avoid 1 death. The 
incremental cost-effectiveness ratio (ICER) was at least $1,000,000 
per QALY gained for all 4 strategies compared with no monitoring. 
It was higher in strategies with higher frequency and longer moni-
toring duration. The results remain robust in the 1-way sensibility 
analyses and the probabilistic sensitivity analysis, indicating that the 
absence of monitoring strategy had the highest probability of cost-
effectiveness for willingness-to-pay under $1,000,000.
Conclusion: Current WBC monitoring based on current national 
detection guidelines do not appear to be cost-effective. New guide-
lines are needed to improve WBC monitoring in schizophrenic 
patients receiving clozapine.
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